Why Novanta’s June healthcare conference appearance matters after its Q1 revenue rebound
Medtech suppliers are under pressure to prove growth quality. Novanta’s Jefferies appearance may sharpen the investor debate.
Why Knox Lane is taking Cross Country Healthcare private in a $437m all-cash deal
Healthcare staffing is still under pressure. Knox Lane’s $437m Cross Country Healthcare deal turns that reset into a private equity wager.
Can Contineum Therapeutics’ PIPE-791 become more than an IPF drug after fresh pain data?
Contineum Therapeutics advances PIPE-791 in IPF and chronic pain while extending cash runway into 2029. Find out what comes next.
Why Indivior’s Delaware redomiciliation matters more than a corporate address change
Find out how Indivior’s move to the United States reshapes governance, regulation, and investor perception in addiction treatment biotech.